Breast cancer: early diagnosis and effective treatment by drug delivery tracing by Shamsi, Mahdiyeh & Pirayesh Islamian, Jalil
45
Nuclear Medicine Review 2017, 20, 1: 45–48
DOI: 10.5603/NMR.2017.0002
Copyright © 2017 Via Medica
ISSN 1506–9680
www.nmr.viamedica.pl
Review
Correspondence to: Jalil Pirayesh Islamian, MD 
Immunology Research Center, Tabriz  
University of Medical Sciences, Tabriz, Iran
E-mail: mahdiyehshamsi@yahoo.com
Breast cancer: early diagnosis  
and effective treatment by drug  
delivery tracing
Mahdiyeh Shamsi, Jalil Pirayesh Islamian
Department of Medical Physics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
[Received 16 II 2015; Accepted 12 X 2016] 
Abstract
Breast cancer is the most frequent cancer in women and it is the main reason of cancer-related deaths of women worldwide. 
Different types of breast cancer diagnostic examinations are also available, such as mammography, MRI, biopsy, ultrasound 
and molecular imaging. Radionuclide-based imaging methods including SPECT and PET are useful in early diagnosis and 
treatment of the cancer. The radiolabeling of chemo drugs with nanoparticles should be recommended from the standpoint of 
an early diagnosis and effective treatment of breast cancer.
KEY words: breast cancer, radiotracer, diagnosis, chemotherapy
Nucl Med Rev 2017; 20, 1: 45–48
Background
Incidence of breast cancer, as the most frequent cancer in 
women, has globally increased in recent years. Therefore, breast 
cancer is the main reason of cancer-related deaths of women 
worldwide [1–3]. In 2014, an estimated 232,670 new cases of 
invasive breast cancer were expected to be diagnosed in women 
in the U.S.; along with 62,570 new cases of non-invasive (in situ) 
breast cancer. About 40,000 women in the U.S. were expected to 
die from breast cancer during 2014. Family history, gender, age, 
genetics, bad lifestyle are risk factors in breast cancer, especially 
gender (being a woman) and age (growing older) [1, 4–7].
Conventional treatments available for breast cancer include 
surgery, chemotherapy, radiation therapy, hormonal therapy, or 
combination therapy [1, 6]. The accurate and early non-invasive 
detection of malignant disease is an important factor in the treat-
ment and prognosis of a cancer patient [8]. Different types of breast 
cancer diagnostic examinations are also available, such as mam-
mography, breast MRI, biopsy, ultrasound and molecular imaging. 
Early detection of the disease is a key to beat breast cancer and 
improve the chance of treatment successful at early stages. How-
ever, early detection will not prevent breast cancer, but it can help 
find when the probability of successful treatment is the greatest [6].
Significant improvement in diagnosis and therapeutic efficacy 
can be achieved only by developing effective approaches based on 
a comprehensive understanding of the molecular mechanisms of 
tumor metabolism [9]. Many studies show that being aware of 
the precise pathway molecular mechanisms in the term of cellular 
diagnosis in initial stages of the growth of a tumor could have 
a significant impact in successful treatment. Molecular imaging may 
provide a non-invasive assessment of biological and biochemical 
processes in living subjects [9–11].
Molecular imaging is now extending the applications of imag-
ing in drug discovery and development in the initial stages of clinical 
trials and has the potential to considerably accelerate the treatment 
and diagnosis process [10–12]. Another important application of the 
technique in the area of diagnosis and treatment of cancer is the lo-
calization, staging, monitoring the response to treatment, making the 
pathologists cancer [9]. Nuclear imaging devices, such as PET and 
SPECT scans uses radioactively tagged tracer molecules to create 
functional images on the biochemistry or physiology of the subject (e.g. 
by chemotherapeuticals) [13, 14]. Nuclear imaging diagnosis modali-
ties play also an important role for conducting research on the biology 
of human diseases and developing new treatment approaches.
Chemotherapy for breast cancer
Chemotherapy is the use of anti-cancer drugs as a systemic 
treatment to treat cancer [6, 15–17]. Chemotherapy modalities ad-
juvant therapy and neoadjuvant chemotherapy chemotherapeu-
tics delivered after and before surgery, respectively [6, 15]. Many 
types of chemotherapy drugs are used to treat breast cancer that 
works in different ways and can be given in different combina-
tions [15, 16]. Some drugs that are used in together includes Cy-
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clophosphamide (Cytoxan), Doxorubicin (Adriamycin) or Epirubicin 
(Ellence), 5-fluorouracil (Adrucil), Methotrexate (Rheumatrex), 
Paclitaxel (Taxol) or Docetaxel (Taxotere), Herceptin and 2-de-
oxy-D-glucose (2DG) [1, 17]. A number of previous studies have 
shown that combination chemotherapy is the most effective treat-
ment regimens based on just one drug [16–18]. This is because 
the different drugs act in slightly different ways, so together they 
increase their ability to kill cancer cells and by having a potentially 
greater impact induce the less severe side effects [15, 17].
Doxorubicin (DOX), as an anticancer drug anthracycline an-
tibiotic with potent antineoplastic has effective properties against 
a wide variety of malignancies, such as non-Hodgkin’s lymphoma, 
acute lymphoblastic leukemia and is also considered as the most 
effective drug in the treatment of breast cancer [12, 19, 20]. The 
planar aromatic chromophore portion of doxorubicin  interact with 
topoisomerase II by inhabitation of normal function of the enzyme 
which hinders relegation of the DNA strands and ultimately induces ir-
reversible DNA breaks [12, 19–21]. Despite of the effectiveness of 
chemotherapy by doxorubicin, the therapeutic dose in a single 
application causes severe side effects, especially on myocard [19].
The glucose analog, 2DG, is clinically proven an inhibitor of 
glycolysis and preferentially accumulate in cancer cells. 2DG 
is an anti-cancer drug also for breast cancer which has the ability 
to poison the cells in vitro and inhibits the tumor growth in vivo. 
This anti cancer also considered as an ideal adjuvant for enhancing 
the efficacy of chemotherapy in the treatment of the drug-resistant 
cervical cancers [1, 19, 22]. Enhancing the cytotoxicity of cisplatin 
and doxorubicin is one of the abilities of 2DG [1, 22].
Many chronic side effects of Doxorubicin has limited the 
prescribed dose for a patient [22]. According to the results of 
previous studies, the combination of 2DG and doxorubicin have 
a significant cell killing capability in breast cancer cells [1, 22].
Nanoparticles for therapy breast cancer
Nanoparticles (NPs) were well defined in character and size 
with the dimensions from 1 nm to 100 nm that can be prepared 
using different targeting agents in the design of tumor-targeting 
carriers, resulting in the enhanced diagnosis and/or therapy of 
cancer [23–25]. Different nanoparticle types contain Iron Oxide, 
Gold, Silver, Carbon Nanotubes, Quantum Dots, polymer- or 
liposome-based [23].
One of the greatest challenges is defining the ideal targeting 
agent or agents to selectively and effectively transport nanoparticle 
structures in cancerous tissue [26, 27]. Generated smart agents with 
drug delivery and molecular targeting capabilities, developed by 
loading nanoparticles using antibodies is also accounted a thera-
peutic approach for breast cancer therapy [26, 27]. Doxorubicin 
has been framed with a liposome delivery system into nanoparticle, 
it was shown that the compound preserves the efficacy of the drug 
and reduces cardiac toxic effects [28]. Encapsulated dextran–doxo-
rubicin conjugate using chitosan nanoparticles as a carrier have 
been used in tumor targeted delivery. After 4 weekly injections, 
intravenously, in mice, the tumor volume of those treated with 
the encapsulated conjugate being only 60% of treated with the 
conjugate alone [29].
Conjugates of 2DG and poly (ethylene glycol)-co-poly (trimeth-
ylene carbonate) nanoparticles (DGlueNP) of ~71 nm diameter 
have been developed as a potential dual-targeted drug delivery 
system in glioma treatment. In vivo fluorescent image indicated that 
DGlueNP had high specificity and efficiency in intracranial tumor ac-
cumulation. After intravenous administration at a dose of 100 mg/kg 
blank DGlueNP per day for a week, acute toxicity to hematologi-
cal system, liver, kidney, heart, lung and spleen in mice, in initial 
safety tests, was not shown. In comparison with nonglucosylated 
nanoparticles (NP), a significantly higher amount of DGlueNP 
was internalized by RG-2 glioma cells through caveolae-mediated 
and clathrin-mediated endocytosis [30].
2-DG conjugated meso-2,3-dimercaptosuccinic acid coat-
ed g-Fe2O3 nanoparticles were incubated with Hela cells for 
4, 8 and 12 hours, the 2-DG-conjugated nanoparticle showed 
a significant uptake in cells compared to the non-targeted 
counterparts [31].
Early detection of breast cancer  
in molecular stage
Radionuclide-based imaging methods including SPECT and 
PET, are useful in early diagnosis and treatment of the cancer 
in the initial stages of clinical testing [12, 23]. The technique 
can be used in early detection of a wide variety of malignancy, 
also breast cancer. Some radioisotope for SPECT imaging 
involves [99mTc ]-technetium, [111In]-indium, [67Ga]-gallium, [131I] 
iodine. 99mTc is the most commonly used radioisotope because 
of its ideal physical properties, such as its short half-life (ap-
proximately 6 h) and with g-photon emission of a single energy 
at 140 keV. These properties are favorable from the point of view 
of both effective imaging and patient safety. In addition, it can 
be also easily produced by a generator system (99Mo/99mTc 
generator) [14, 23, 24].
Considerable candidates for improved molecular imaging are 
NPs because of their unique size and physical properties. These 
properties allow bio-interaction and visualization of biological 
events enhanced at subcellular levels [24].
Methotrexate (MTX) is an important anticancer agent for the 
treatment of a variety of malignant tumors such as breast cancer. 
MTX and BN peptide analogs radiolabeled with 99mTc for tracing the 
approach. In vitro cell-binding and internalization on breast cancer 
and prostate cancer cell lines have shown a high affinity and speci-
ficity. In addition, in vivo the radio-conjugate approach displayed 
a significant internalization (values ranged between 19–35%) into 
the tumor cells. The combination of favorable in vitro and in vivo 
properties may render 99mTc-MTX-BN as a potential candidate for 
the targeted imaging and eventually for radionuclide therapy (when 
labeled with an appropriate radionuclide) [32].
In a study, Diethylenetriaminepentaacetic acid (DTPA) and 
deoxyglucose (DG) radiolabeled with 99mTc. Cellular uptake as-
say in vitro was performed using a human mammary cancer cell 
line. Biodistribution was also calculated as percentage of injected 
dose per gram of wet tissue in vivo. Tumor-to-non-target tissue 
ratios were calculated from the corresponding tissue concentra-
tions. [99mTc]–DTPA–DG imaging was obtained with a dual-head 
gamma. The results have shown a rapid blood clearance of the 
complex [99mTc]-DTPA-DG with the main route of clearance via 
the kidneys and also suggested a potential imaging agent in the 
detection of the tumor [8].
47www.nmr.viamedica.pl
Mahdiyeh Shamsi et al., Breast cancer: early diagnosis and effective treatment
Review
In another study the bovine serum albumin nanoparti-
cles (BSANPs) and pheophorbide-a (PH-A) were labeled 
with 99mTc. The biodistribution of99mTc-PH-ABSANPs in healthy 
female rats showed high uptake in the breast and uterus. 
99mTc-PH-A-BSANPs were taken up to human breast adenocar-
cinoma cell line (MCF-7). In conclusion, 99mTc-PH-A-BSANPs are 
suitable for imaging and drug delivery in the field of nanomedicine, 
and may be used as site-specific tumor imaging agent [21, 33].
Radiolabel doxorubicin with Technetium-99m as a scintigraphic 
marker of high DNA turnover/intercalation in malignant cells. Blood 
kinetics was studied in an adult rabbit after intravenous (dorsal ear 
vein) injection of the radiopharmaceutical and the biodistribution, 
and the excretory route of 99mTc doxorubicin was studied in male 
Wistar rats. Ehrlich ascites tumor (EAT) cell line was injected sub-
cutaneously into Balb/c mice. Scintigraphy of tumor-bearing mice 
was performed after intravenous injection of 99mTc-doxorubicin into 
the tumor-bearing mice. This scintigraphic approach, therefore, 
could be a powerful tool for cancer detection at early stage espe-
cially in developing countries [21]. The doxorubicin-loaded NPs ra-
diolabeled by 99mTc have an effective drug targeting with a potential 
clinical applications such as early detection [34]. Tc-99m sestamibi 
has good physical characteristics for scintimammography, and 
consequently high diagnostic accuracy. Moreover, this technique 
represents real advance in the noninvasive management of patient 
with early stage breast cancer [35, 36].
Conclusions 
Molecular imaging tools including SPECT and PET are highly 
effective, safe and painless diagnostic imaging modality.The early 
detection of malignant diseases is an useful assessment to select 
most effective treatment. Molecular imaging is commonly used in 
diagnosis and treatment of breast cancer. One of the mostpromis-
ing research areas is investigational diagnostic use of nanoparti-
cles and radioactive substances. Nanoparticle imaging with MRI, 
optical and nuclear medicine techniques have also been applied 
on a research and clinical level. Radiolabeled nanoparticles have 
proven to be promising tools in the diagnosis and therapy of ma-
lignant processes.
Chemodrugs such as 2DG and Doxorubicin in combination 
with NPs when labeled with radiotracer such as 99mTc can im-
prove an efficiency of diagnostic and treatment of breast cancer. 
A multifunctional system of this nature could improve the overall 
effectiveness of cancer therapeutics.
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